AbbVie Inc. closed $6.12 short of its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Glaukos (GKOS – Research Report) yesterday and set a price target of $139.00. Ryan ...

Discover the FlexShares Quality Dividend Defensive Index Fund (QDEF) for potential capital gains with limited volatility and ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Investing in “dividend powerhouses” — companies with stellar dividend payments and growth histories — is a smart way to ...

Archon Perry Siatis is a FOUNDER of the Ecumenical Patriarch Bartholomew Foundation. In addition to serving as Vice Chair of the Archon Youth Participation Activities Committee, he is also a founding ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.